Please login to the form below

Not currently logged in

Novartis bolsters radioligand therapy pipeline with new licence agreement

Radioligand therapies are a new potential class of precision oncology drugs

Novartis has secured exclusive worldwide rights to develop and commercialise a library of radioligand therapies targeting fibroblast activation proteins (FAP) through a new licence agreement.

Novartis has licensed the agents, including two assets known as FAPI-46 and FAPI-74, through an assignment agreement with iTheranostics, an affiliate of SOFIE Biosciences.

FAPs are expressed on the cell surface at low levels in most normal adults tissues, but are found to be over-expressed in common cancers, with high FAP expression on cancer-associated fibroblasts generally associated with worse prognosis in solid tumours.

“We continue to invest in radioligand therapy as one of the four unique platforms of Novartis Oncology. We believe working across multiple approaches is the key to reimagining cancer care,” said Susanne Schaffert, president, Novartis Oncology.

“FAP is an exciting target and these agents are a great fit with our radioligand therapy pipeline, which we are actively investigating across multiple tumour types. We believe this technology has the potential to transform many patients’ lives,” she added.

The agreement follows the announcement from Novartis last week that its investigational radioligand therapy, 177Lu-PSMA-617, hit both primary endpoints in a phase 3 trial in patients with advanced prostate cancer.

The phase 3 VISION study, an open-label study evaluating the efficacy and safety of 177Lu-PSMA-617 in patients with progressive PSMA-positive metastatic castration-resistant prostate cancer (mCRPC), compared the radioligand therapy plus best standard of care (SoC) to SoC alone.

In this trial, 177Lu-PSMA-617 met the primary endpoints of overall survival and radiographic progression-free survival, with significant improvements on both these markers.

The detailed results from the VISION trial are due to be presented at an upcoming medical meeting and included in regulatory submissions in the US and EU.

Radioligand therapies have emerged as a new potential class of precision oncology drugs. They combine two elements – a targeting compound (ligand) with a radioactive isotope, with the aim of causing DNA damage to inhibit tumour growth and replication.

For example, 177Lu-PSMA-617 binds to prostate cancer cells that express PSMA – a transmembrane protein – with high tumour-to-normal tissue uptake.

After 177Lu-PSMA-617 binds to these cells, emissions from the radioisotope damage tumour cells and impact their ability to replicate which can trigger cell death.

Novartis said this therapeutic approach limits damage to the surrounding normal tissue while enabling targeted delivery of radiation directly to the tumour.

Article by
Lucy Parsons

31st March 2021

From: Research



PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs


Add my company

AMICULUM® is an independent global healthcare communications, consulting and learning business with a global team of >220 healthcare communications professionals,...

Latest intelligence

InSite Events™ National Pharma Meeting: A Customer Story
How our client leveraged Impetus Digital’s white-glove service, 360° coverage and care, and award-winning InSite Events™ platform to successfully transfer their annual national meeting online....
Fear or encouragement, which is best to drive behaviour change?
The communications industry depends on fear of the perceived loss of something, in order to create the hope found in a product benefit. But, if if left too long unchecked,...
The unheard, unseen, and uncorrected effects of COVID-19
The disproportionate effects of the pandemic have been highlighted amongst ethnic minorities, so is it likely that ethnic minorities will be more worried about participating? And could this exacerbate inequalities...